JOURNAL OF NUCLEAR MEDICINE

简称 J NUCL MED ·UNITED STATES ·出版周期 Monthly ·年均收录 329 篇

9.1

最新影响因子

10.70%

自引率

很难

投稿难度

平均1.0个月

审稿周期

期刊简介

JOURNAL OF NUCLEAR MEDICINE（ISSN 0161-5505）是一本专注于核医学领域的国际学术期刊，由美国核医学与分子影像学会（SNMMI）出版，出版地为美国，出版周期为月刊。该期刊的影响因子较高，属于SCI收录期刊，并在中科院分区中通常位列医学或核医学领域的较高分区。它不是开放获取（OA）期刊。该杂志的发文特点集中在核医学与分子影像学的前沿研究，包括放射性药物开发、影像技术应用、疾病诊断与治疗等方向，尤其注重临床转化研究。其质量较高，审稿严格，学术声誉良好，但投稿竞争激烈，拒稿率较高，且版面费可能较贵，非OA模式可能限制部分读者获取全文。

影响因子趋势

近期发表

PSMA PET/CT and Multiparametric MRI Before Prostate Biopsy 2026-09-03

Radioiodine Spill–Induced Radiation Dermatitis 2026-09-03

Reply to “Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations” 2026-09-03

A Conversation Between Stefano Fanti and Johannes Czernin 2026-09-03

Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations 2026-09-03

A Prospective, Single-Center, Single-Arm, Exploratory Study of 177 Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 2026-09-03

PET Imaging of Tumor-Associated Macrophage Dynamics and Response to Clinical Treatment for Potential Translation 2026-09-03

Evaluating Suspected Tumor Recurrence with Epidermal Growth Factor Receptor–Targeted [ 89 Zr]Zr-Panitumumab PET/CT 2026-09-03

Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses 2026-09-03

Comment on FDA Approval Pathways 2026-09-03